Finance, Grants, Deals

Nanobiotix increases its capital

Country
France

Nanobiotix SA, which produces nanoparticles designed to increase the efficacy of radiotherapy, has increased its capital with a €28.1 million offering on the NYSE Euronext Paris exchange. Proceeds will be used to advance its lead cancer agent – a medical device.

Horizon Discovery IPO over-subscribed

Country
United Kingdom

Horizon Discovery Group Plc has raised £68.6 million with an initial public offering on the London Stock Exchange’s Alternative Investment Market, well in excess of the originally targeted £25 million. Horizon will use the funds to expand the sales of its genomics research tools.

Evotec purchases in-licensing firm

Country
Germany

Evotec AG has announced the acquisition of a small asset management company, Bionamics GmbH, to help it accelerate the translation of academic innovations into assets for the biotech and pharmaceutical industry. Financial terms weren’t disclosed.

BMS gets access to new checkpoint targets

Country
United States

Bristol-Myers Squibb Company is set to gain access to new targets for the development of checkpoint inhibitors against cancer under a licensing deal with Five Prime Therapeutics Inc carrying an upfront payment of  $20 million.

BioInvent in rights offering

Country
Sweden

BioInvent International AB, which is developing three antibodies to treat cancer, plans to raise SEK 48.9 million (€5.5 million) with a rights offering on the NASDAQ OMX Exchange in Stockholm. The proceeds will support the company’s ongoing research.

DiaGenic to raise NOK 50 million with rights issue

Country
Norway

DiaGenic ASA, a specialist in gene expression technology, is raising NOK 50 million (€6 million) with a rights offering on the Oslo Stock Exchange. The offering comprises 100 million new shares priced at NOK 0.50 per share.

TxCell secures partnership, plans IPO

Country
France

The French biotechnology company TxCell SA has signed an option agreement to license its lead cell therapy for inflammatory bowel disease (IBD) to Ferring International Center SA, and simultaneously announced plans to list its shares on Euronext Paris.

Inotrem raises €18 million for sepsis

Country
France

Inotrem SA, a French start-up with a new approach for treating sepsis, has raised €18 million in a Series A round, the largest early funding round in Europe so far this year. The company was co-founded in February 2013 by Jean-Jaques Garaud, formerly of Roche.

Galapagos sells two service companies for €134 million

Country
Belgium

Galapagos NV of Belgium said it has sold two of its early-stage service companies, BioFocus and Argenta, to Charles River Laboratories International Inc of the US for €134 million. It retains a third service company in Croatia.

Vectura floats equity to purchase Activaero

Country
United Kingdom

The Vectura Group Plc, which develops and sells products for airway-related diseases, has raised £52 million with a primary offering on the London Stock Exchange in connection with its acquisition of Activaero GmbH, a German specialist in vapor delivery devices called nebulisers, for about £108 million.